I'm a science journalist for @statnews.com looking to talk with folks who applied to biomedical Ph.D. programs and had offers rescinded earlier this year. What have you been up to since then? You can reach me at [email protected] or via Signal (username jwosen.27). #journorequest

Latest: A race to develop a new class of narcolepsy drugs could not only transform treatment for patients with the rare sleep disorder, but also many people with common health conditions like Alzheimer's and depression who struggle to stay awake

Novo Nordisk, seen as lagging in obesity drug race, says it’s playing the long game. Via @elaineywchen.bsky.social www.statnews.com/2025/06/25/n...

From #ADA25: Full results suggest Novo's CagriSema is comparable to Lilly’s Zepbound on safety and efficacy Weight loss looks to be plateauing at the end of late-stage studies, raising Qs around how much more weight patients can lose on the drug

Latest from #ADA25: Novo's injectable amycretin showed substantial weight loss in an early study, but similar efficacy across different doses and high rates of side effects raise questions about which dose Novo will pursue going forward

New video- my new @statnews.com colleague @chelseacirruzzo.bsky.social and I chat about RFK Jr.'s dismissal of all the members of ACIP, CDC's vaccine advisory board. Also I'm going to be doing a video every week now so please wish me luck (and like & subscribe plz) youtu.be/brVDswDpaeQ

LATEST: A conservative culture cost Novo Nordisk its lead in the obesity drug race, former employees told me It wanted to tread carefully as the first mover in the space, and its belief in Ozempic/Wegovy blinded it to other candidates, they said

Yesterday, we dove into all the data on chronic disease in the U.S. So, what can actually make a dent in it? Here are 3 big ideas: www.statnews.com/2025/05/21/r...

NEW: How RFK Jr. goes about solving the chronic disease epidemic depends on his top concerns. Here, we break down the nation's health into 9 "priorities" — using original data analysis you can't find elsewhere! — and let you choose yours. W/ @jaspar.bsky.social: www.statnews.com/2025/05/20/k...

The explosion of compounded GLP-1 offerings is ending, and many patients are left with no good options. Telehealth companies and compounders are pursuing workarounds that may be riskier. At the same time, patients still can't afford the branded drugs. w/ @katiepalmer.bsky.social

WaPo has the numbers on those NIH advisory board purges @jasonmast.bsky.social and I first reported on last month. Six percent of White males who serve on boards were fired, compared with half of Black and Hispanic females and one-quarter of all females, according to an analysis by board chairs.

What do the Trump administrations tariffs mean for the pharmaceutical industry? New short vid @statnews.com h/t to my STAT colleagues @elaineywchen.bsky.social and Ed Silverman

RFK Jr. vowed to promote “radical transparency” at HHS. But today the dpt made major cuts to teams across its agencies that handle communications, media relations, and FOIA requests - w/ @lizzylawrence.bsky.social, @isabellacueto.bsky.social

HHS workers affected by today's announcement/ RIF: Tell us what's going on! You can do so confidentially/anonymously through this form. I'm also at isabellacueto.03 on Signal, or send a DM. www.statnews.com/2025/03/27/h...

New: The NIH has canceled funding for a landmark diabetes study — at a time when RFK Jr. and the rest of the MAHA movement is focused on addressing chronic diseases, including diabetes. Smart story from @elaineywchen.bsky.social www.statnews.com/2025/03/17/t...

Weldon out as CDC nominee, hours before he was set to appear in front of the Senate: www.statnews.com/2025/03/13/t...

Eli Lilly's obesity and diabetes drugs are paying off for top executives. CEO Dave Ricks took home $114 million last year, and he and other leaders also were treated to a "leadership meeting" at last summer’s Olympics in Paris. More w/ @elaineywchen.bsky.social: www.statnews.com/2025/03/11/e...

Breaking: RFK Jr. moves to quietly eliminate public comment from HHS's decision making: www.statnews.com/2025/02/28/r...

Pfizer yesterday revised its DEI webpage to emphasize the importance of "merit," joining other companies seeking to align with the Trump administration @jaspar.bsky.social and I laid out all the deletions and insertions in our story www.statnews.com/2025/02/27/p...

Incredible: we're reaching a point where new weight loss drugs might be *too* effective, leading to health risks. from @elaineywchen.bsky.social www.statnews.com/2025/02/20/t...

NEW: Patients in trials of Lilly's next-gen obesity drug tell me they think they're losing too much weight. One started skipping doses, another is making himself eat caloric foods. This is part of what some see as a risky race for more weight loss www.statnews.com/2025/02/20/t...

Looking to talk with federal employees with disabilities who were terminated this weekend, especially folks hired through Schedule A or disabled veterans. Please boost! #disability #journorequest

Scoop: The cuts to FDA included head of medical device safety Rusty Segan. He was hired in September after a lengthy search by the agency. www.statnews.com/2025/02/18/f...

The Trump administration terminated employees at the Food and Drug Administration on Saturday night, three sources told STAT. If you were affected or know more about the layoffs, feel free to message me on Signal at lizzylaw.53 www.statnews.com/2025/02/15/t...

New from me: Here it is, everything I know about every change I've been monitoring on data.cdc.gov plus an archive of every file that's been removed or altered. www.statnews.com/2025/02/14/t...

If you are one of the #CDC #HHS #FDA #NIH employees who have learned today that your employment is being abruptly ended, we want to hear from you. @altcdc.bsky.social www.statnews.com/2025/02/14/f...

BREAKING: HHS to fire thousands of public workers on probationary employment this afternoon. Top officials at CDC, NIH, briefed this morning.

As outcry builds over Trump cuts to NIH payments, drugmakers are MIA www.statnews.com/2025/02/11/n... by @adamfeuerstein.bsky.social

🚨 Excited to officially announce I'm writing a new newsletter for @statnews.com! AI Prognosis starts Feb 12. It's all about AI in healthcare, medicine & biotech. (If you sign up before Jan 20, you'll get the first 4 issues free, even if you don't have STAT+!) www.statnews.com/signup/ai-pr...

Friday night news from @jonathanwosen.bsky.social, @usha.bsky.social, @jasonmast.bsky.social and myself. Story is developing and will be updated www.statnews.com/2025/02/07/n...

Trump administration allows some global aid to restart, but concerns remain on impact of USAID shutdown

What brain drain could look like at the FDA, new from me: www.statnews.com/2025/02/07/f...

Lawmakers ask the FDA to review Hims’ Super Bowl ad for "misleading" patients, foreshadow that they plan to introduce legislation to address ads that omit safety info, via @mariojoze.bsky.social

Week two of the Trump administration is underway. If you want to understand the ongoing chaos in federal health agencies, follow me and my @statnews.com colleagues. go.bsky.app/7odqGRR

my colleagues @statnews.com & I are continuing to report on changes to NIH and other federal agencies if you are at an event/study section etc that is canceled or changed do reach out you can reach me here, email (anil{dot}oza{at}statnews.com) or signal (aniloza.16)

Eli Lilly is considering offering more doses of its obesity drug Zepbound in vials at lower cost The CEO acknowledged to us that some people have turned to compounding due to "real cost pressures" and the current entry price of the vials can be "too high"

Good morning from #JPM25, where some companies like Cigna, Centene, Oscar, and Walgreens have dropped out of the conference. www.statnews.com/2025/01/13/j...

FDA shifts toward the importance of obesity drugs in new guidance It calls obesity a disease instead of a health risk. It removes language that lifestyle changes are “the cornerstone” of obesity management. And it eases recommendations for trials in kids

BREAKING: Patrizia Cavazzoni, head of FDA’s drug center, to leave the agency www.statnews.com/2025/01/10/f...

On this week's podcast, we preview JPM and a potential surge in deal-making this year. Stay tuned for next week's episode — we'll be recording in San Francisco and bringing on Eli Lilly CEO Dave Ricks.

The advent of generic liraglutide (an older GLP-1 drug) could help Medicare negotiate a lower price for Ozempic and Wegovy — via my colleague John Wilkerson

In a less-than-ideal turn of events, I was affected by the layoffs @statnews.bsky.social upon returning from maternity leave. I have loved my time at STAT and am heartbroken, but here: able and willing to work, open to all opportunities. Find me at [email protected]!

I wrote about gender-affirming surgery — what it means to the people that get it, its evolution as a professional specialty in the U.S., and how the incoming administration could put all of that at risk: www.statnews.com/2024/12/23/g...

What Novo Nordisk’s disappointing trial results mean for the obesity drug market — I break down the key implications of today's CagriSema results

A closely watched next-gen obesity treatment from Novo Nordisk misses the mark in a pivotal trial, results that cast into doubt the future competitiveness of the company in the booming weight loss market.

The FDA said today that the tirzepatide shortage is over, reiterating its decision in October, but pharmacies still seem to have trouble ordering enough of the drug. One patient in Phoenix: The shortage “wasn’t resolved then, and it isn’t resolved now.”

Last podcast of the year -- we chat about how Marty Makary might lead the FDA w/ @lizzylawrence.bsky.social, our burning biotech Qs for next year, and our favorite holiday potato dishes

NEW: Some consider him a fearless truth-teller with a deep respect for science. Others consider him a contrarian for contrarian’s sake, opining on matters for political clout. Which Marty Makary would run the FDA? www.statnews.com/2024/12/17/m...

Novo Holdings is set to close its $16.5 billion acquisition of Catalent after FTC declines to challenge the deal

This has implications for the wider alternative market for GLP-1s, where tele-healths are offering both brand name and compounded copies of drugs like Zepbound and Wegovy. I recently did an explainer on how this whole marketplace works. youtu.be/2w-MCLEtZ10